A service disruption on campus brought down many University services and applications for much of Thursday, though the issue ...
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...
A cold-shooting night for Oregon Tech came at the wrong time of the season, as No. 3-ranked Arizona Christian held the ...
Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...
On Tuesday, March 25, the Office of Information Technology will upgrade the GlobalProtect VPN client.
The study suggests that omalizumab could become a safer, more effective alternative to OIT for people with highly sensitive ...
Patrick Barry extended his record hitting streak to 36 games, combining for four hits on the day, as Oregon Tech split a ...
The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical trial found that omalizumab (Xolair) was more effective than oral ...
The primary endpoint of OUtMATCH 2 required participants to tolerate at least 2 g (cumulative 4044 mg) for each food — nearly four times the amount in the phase 3 Palforzia trial of peanut OIT.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback